Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.6%

7 terminated/withdrawn out of 34 trials

Success Rate

63.2%

-23.3% vs industry average

Late-Stage Pipeline

18%

6 trials in Phase 3/4

Results Transparency

58%

7 of 12 completed trials have results

Key Signals

7 recruiting7 with results

Enrollment Performance

Analytics

N/A

11(52.4%)

Phase 4

6(28.6%)

Phase 2

2(9.5%)

Phase 1

2(9.5%)

21Total

N/A(11)

Phase 4(6)

Phase 2(2)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (34)

Showing 20 of 34 trials

NCT06455787Not ApplicableRecruiting

J-Valve Transfemoral Pivotal Study

Role: collaborator

NCT04763460Not ApplicableWithdrawn

Effects of CRT Optimization as Assessed by Cardiac MR

Role: lead

NCT07131631Recruiting

Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic Resonance

Role: lead

NCT07212816Not Yet Recruiting

Detection of Atrial Fibrillation Through Voice Signal Processing

Role: collaborator

NCT03413423Not ApplicableActive Not Recruiting

Post Acute Cardiac Event Smoking (PACES) Study

Role: collaborator

NCT06804980Phase 4Recruiting

DESIFOR-EXPAND (MHIF)

Role: lead

NCT05187351Active Not Recruiting

Native Coronary Artery Instead of SAphenous Vein Graft Intervention for Treatment of Significant Saphenous Vein Graft Lesions

Role: lead

NCT04077762Not ApplicableRecruiting

Radial Vs. State-Of-The-Art Femoral Access for Bleeding and Access Site Complication Reduction in Cardiac Catheterization (REBIRTH)

Role: lead

NCT05440084Terminated

Impact of CTO PCI (Chronic Total Occlusion Percutaneous Intervention) on Regular Physical Activity

Role: lead

NCT05305911Phase 2Recruiting

Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

Role: lead

NCT02973815Not ApplicableCompleted

New Ulm at HOME (Healthy Offerings Via the Mealtime Environment), NU-HOME

Role: collaborator

NCT05531084Not ApplicableNot Yet Recruiting

Safety and Effectiveness of Surgeon-Modified Stent Grafts forTreatment of Complex Aortic Aneurysms

Role: collaborator

NCT04525937Unknown

Racial and Economic Disparities and Unmet Needs in Patients With Severe Aortic Valvular Disease

Role: lead

NCT03889314Phase 4Unknown

The DEtermining Statin Intolerance FOr Rosuvastatin (DESIFOR) Trial

Role: lead

NCT02061436Unknown

Prospective Global Registry for the Study of Chronic Total Occlusion Intervention

Role: lead

NCT05100940Recruiting

Progress Complication

Role: lead

NCT05100992Recruiting

Progress Bifurcation Global Registry

Role: lead

NCT05065073Phase 4Unknown

Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography

Role: lead

NCT03542110Phase 4Terminated

The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial

Role: lead

NCT02784418Not ApplicableWithdrawn

The SHINE-CTO Trial

Role: lead